MAP2K7 and colorectal cancer: Recent evidence has demonstrated the advantages of using BRAF-targeted therapies, either alone or in combination with MEK inhibition and epidermal growth factor receptor-targeted treatment, in patients diagnosed with advanced colorectal cancer carrying the BRAF V600E mutation [74].